GlassScriptPhysician profile
Carolyn Greer
NPI 1568458990
$23,443.45
in general payments reported to CMS, 2019-2025
21 companies · $453 in 2025
The $453 reported for 2025 was more than what a typical Addiction Medicine (Psychiatry & Neurology) provider received nationally (typical 2025 total: $152).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $36.31 · 2020: $12.88 · 2021: $1,706 · 2022: $20K · 2023: $848 · 2024: $673 · 2025: $453.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,974.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,973.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pear Therapeutics (US), INC. | $20,406.33 | 2021-2022 | |
| Abbvie INC. | $797.04 | 2022-2025 | |
| Axsome Therapeutics, INC. | $516.55 | 2022-2025 | Auvelity |
| Otsuka America Pharmaceutical, INC. | $340.59 | 2022-2024 | Rexulti, Abilify Maintena |
| Idorsia Pharmaceuticals US INC | $243.16 | 2022-2023 | Quviviq |
| Lilly USA, LLC | $237.63 | 2023-2025 | Mounjaro, Zepbound |
| Corium, LLC | $150.82 | 2023-2025 | Azstarys |
| Eisai INC. | $143.55 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $136.03 | 2022-2024 | Uzedy |
| Sunovion Pharmaceuticals INC. | $102.63 | 2019-2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $63.53 | 2024-2025 | Caplyta |
| Merck Sharp & Dohme LLC | $46.04 | 2022-2023 | Belsomra |
| Takeda Pharmaceuticals U.S.A., INC. | $40.03 | 2024 | Trintellix |
| Indivior INC. | $39.79 | 2024 | Sublocade |
| E.R. Squibb & Sons, L.L.C. | $34.33 | 2024-2025 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lundbeck LLC | $33.84 | 2022-2024 | Abilify Asimtufii |
| Alkermes, INC. | $27.57 | 2022-2024 | Aristada, Lybalvi |
| Neurocrine Biosciences, INC. | $23.45 | 2022 | |
| Biogen, INC. | $22.68 | 2024 | |
| Gilead Sciences, INC. | $21.78 | 2023 | |
| Ironshore Pharmaceuticals INC. | $16.08 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Carolyn Greer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.